- Home
- MEGL vs CNSP Comparison
MEGL vs CNSP Comparison
Compare MEGL & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- CNSP
- Stock Information
- Founded
- MEGL 2016
- CNSP 2017
- Country
- MEGL Hong Kong
- CNSP United States
- Employees
- MEGL N/A
- CNSP N/A
- Industry
- MEGL Finance: Consumer Services
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- MEGL Finance
- CNSP Health Care
- Exchange
- MEGL Nasdaq
- CNSP Nasdaq
- Market Cap
- MEGL 4.8M
- CNSP 5.6M
- IPO Year
- MEGL 2022
- CNSP 2019
- Fundamental
- Price
- MEGL $1.27
- CNSP $1.04
- Analyst Decision
- MEGL
- CNSP Hold
- Analyst Count
- MEGL 0
- CNSP 1
- Target Price
- MEGL N/A
- CNSP N/A
- AVG Volume (30 Days)
- MEGL 24.6K
- CNSP 224.0K
- Earning Date
- MEGL 05-06-2025
- CNSP 05-14-2025
- Dividend Yield
- MEGL N/A
- CNSP N/A
- EPS Growth
- MEGL N/A
- CNSP N/A
- EPS
- MEGL N/A
- CNSP N/A
- Revenue
- MEGL $1,645,862.00
- CNSP N/A
- Revenue This Year
- MEGL N/A
- CNSP N/A
- Revenue Next Year
- MEGL N/A
- CNSP N/A
- P/E Ratio
- MEGL N/A
- CNSP N/A
- Revenue Growth
- MEGL N/A
- CNSP N/A
- 52 Week Low
- MEGL $0.41
- CNSP $0.77
- 52 Week High
- MEGL $3.06
- CNSP $800.00
- Technical
- Relative Strength Index (RSI)
- MEGL 49.81
- CNSP 36.68
- Support Level
- MEGL $1.12
- CNSP $0.83
- Resistance Level
- MEGL $1.24
- CNSP $1.37
- Average True Range (ATR)
- MEGL 0.13
- CNSP 0.15
- MACD
- MEGL -0.00
- CNSP 0.07
- Stochastic Oscillator
- MEGL 59.52
- CNSP 44.82
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.